{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:47:54Z","timestamp":1792043274013,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01734-x","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:16:20Z","timestamp":1792041380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Pharmacovigilance Outsourcing Practices in Arab Countries"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-7974","authenticated-orcid":false,"given":"Ibrahim","family":"Abdeldayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-2468","authenticated-orcid":false,"given":"Thamir M","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Palin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"6","key":"1734_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/0141076814568299","volume":"108","author":"A Maynard","year":"2015","unstructured":"Maynard A, Bloor K. Regulation of the pharmaceutical industry: promoting health or protecting wealth? J R Soc Med. 2015;108(6):220\u20132. https:\/\/doi.org\/10.1177\/0141076814568299.","journal-title":"J R Soc Med"},{"key":"1734_CR2","unstructured":"Ideas JS, MD, CEO, Prism. Pharmacovigilance Outsourcing: A Guide | Applied Clinical Trials Online. 2025. https:\/\/www.appliedclinicaltrialsonline.com\/view\/pharmacovigilance-outsourcing-guide. Accessed Jul 2025."},{"key":"1734_CR3","doi-asserted-by":"publisher","unstructured":"Pappa D. The knowledge discovery cube framework: a reference framework for collaborative, information-driven pharmacovigilance. [Application\/pdf]. 2020. https:\/\/doi.org\/10.15126\/THESIS.00850008.","DOI":"10.15126\/THESIS.00850008"},{"key":"1734_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.02.013","author":"J Price","year":"2018","unstructured":"Price J. Pharmacovigilance in crisis: drug safety at a crossroads. Clin Therap. 2018. https:\/\/doi.org\/10.1016\/j.clinthera.2018.02.013.","journal-title":"Clin Therap"},{"issue":"7","key":"1734_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40264-019-00807-4","volume":"42","author":"TM Alshammari","year":"2019","unstructured":"Alshammari TM, Mendi N, Alenzi KA, Alsowaida Y. Pharmacovigilance systems in Arab countries: overview of 22 Arab countries. Drug Saf. 2019;42(7):849\u201368. https:\/\/doi.org\/10.1007\/s40264-019-00807-4.","journal-title":"Drug Saf"},{"key":"1734_CR6","doi-asserted-by":"publisher","DOI":"10.1142\/11228","volume-title":"Cobert\u2019s manual of drug safety and pharmacovigilance","author":"B Cobert","year":"2019","unstructured":"Cobert B, Gregory WW, Thomas J-L. Cobert\u2019s manual of drug safety and pharmacovigilance. WORLD SCIENTIFIC; 2019."},{"key":"1734_CR7","unstructured":"Research ZM. Pharmacovigilance Outsourcing Market Size, Share & Growth Report 2032. Zion Market Research. (n.d.). Retrieved December 16, 2025, from https:\/\/www.zionmarketresearch.com\/report\/pharmacovigilance-outsourcing-market."},{"key":"1734_CR8","unstructured":"Medicines Agency E. Guideline on good pharmacovigilance practices (GVP) Module I\u2014Pharmacovigilance systems and their quality systems [Internet]. 2012 [cited 2020 Aug 2]. Available from: www.ema.europa.eu."},{"key":"1734_CR9","unstructured":"Pharmacovigilance Outsourcing Market Size, Forecast, Analysis 2025\u20132030. Mordor Intelligence. 2025. https:\/\/www.mordorintelligence.com\/industry-reports\/pharmacovigilance-outsourcing-market. Accessed Jul 2025"},{"key":"1734_CR10","unstructured":"Pharmacovigilance Outsourcing Market Share|2026 Forecast [Internet]. [cited 2020 Aug 2]. Available from: https:\/\/www.gminsights.com\/industry-analysis\/pharmacovigilance-outsourcing-market."},{"key":"1734_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40290-017-0183-9","volume":"31","author":"G Furlan","year":"2017","unstructured":"Furlan G, Leeuwen B, Edwards B. Considerations for good pharmacovigilance outsourcing practices. Pharm Med. 2017;31:1\u20136. https:\/\/doi.org\/10.1007\/s40290-017-0183-9.","journal-title":"Pharm Med"},{"key":"1734_CR12","unstructured":"Medicines Agency E. Guideline on good pharmacovigilance practices (GVP) Module I\u2014Pharmacovigilance systems and their quality systems. 2012 [cited 2021 Aug 17]; Available from: www.ema.europa.eu."},{"key":"1734_CR13","unstructured":"ICH E2D post-approval safety data management\u2014Scientific guideline|European Medicines Agency (EMA). 2003. https:\/\/www.ema.europa.eu\/en\/ich-e2d-post-approval-safety-data-management-scientific-guideline. Accessed Jul 2025"},{"issue":"2","key":"1734_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s43441-020-00229-w","volume":"55","author":"B van Leeuwen","year":"2021","unstructured":"van Leeuwen B, Edwards B. The road to pharmacovigilance outsourcing guidance. Ther Innov Regul Sci. 2021;55(2):408\u201314. https:\/\/doi.org\/10.1007\/s43441-020-00229-w.","journal-title":"Ther Innov Regul Sci"},{"key":"1734_CR15","unstructured":"joannaharper. MHRA GPvP Inspectorate Guide to Marketing Authorization Holder Considerations for Agreements with Pharmacovigilance System Service Providers \u2013 MHRA Inspectorate. 2018. https:\/\/mhrainspectorate.blog.gov.uk\/2018\/01\/22\/mhra-gpvp-inspectorate-guide-to-marketing-authorization-holder-considerations-for-agreements-with-pharmacovigilance-system-service-providers\/. Accessed Jul 2025."},{"key":"1734_CR16","unstructured":"Jordan Food and Drug Administration. Pharmacovigilance System Master File (PSMF) inspection findings report (18 March 2018\u201320 February 2020) (Version PV-insp. 1.0\/2020). Jordan Food and Drug Administration. 2020."},{"key":"1734_CR17","doi-asserted-by":"crossref","unstructured":"18th ISoP Annual Meeting \u201cPharmacovigilance without borders\u201d Geneva, Switzerland, 11-14 November, 2018. In: Drug safety. NLM (Medline); 2018, p. 1103\u2013273.","DOI":"10.1007\/s40264-018-0719-2"},{"key":"1734_CR18","unstructured":"League of Arab States. Guideline on good pharmacovigilance practices (GVP) for Arab countries (Version 2). League of Arab States. 2014."},{"key":"1734_CR19","unstructured":"Saudi Food and Drug Authority. Guideline on good pharmacovigilance practices (GVP). Drug sector [Internet]. [cited 2025 Aug 30]. Available from: https:\/\/www.sfda.gov.sa\/ar\/drug\/resources\/DocLib2\/GuidelineonGood Pharmacovigilance Practices (GVP).pdf."},{"key":"1734_CR20","volume-title":"Guide Alg\u00e9rien des Bonnes Pratiques de Pharmacovigilance","author":"Centre National de Pharmacovigilance et de Mat\u00e9riovigilance (CNPM)","year":"2025","unstructured":"Centre National de Pharmacovigilance et de Mat\u00e9riovigilance (CNPM), Agence Nationale des Produits Pharmaceutiques (ANPP). Guide Alg\u00e9rien des Bonnes Pratiques de Pharmacovigilance. Version 2.0. Algeria: Minist\u00e8re de la Sant\u00e9; Minist\u00e8re de l\u2019Industrie Pharmaceutique; December 2025.","edition":"Version 2.0"},{"key":"1734_CR21","unstructured":"Good Pharmacovigilance Practice Tunisian guidelines. 2022."},{"key":"1734_CR22","unstructured":"Good Pharmacovigilance Practice Guideline for Pharmaceutical Companies , Marketing Authorization Holders and their Representatives in Iraq; 2021."},{"key":"1734_CR23","unstructured":"Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care. (2026). Guideline on Good Pharmacovigilance Practice (GVP) in Egypt for Pharmaceutical Products (Version 3). Egyptian Drug Authority. Guideline on Good Pharmacovigilance Practice (GVP) in Egypt\u2013Version 3, 2026."},{"key":"1734_CR24","unstructured":"\u062c\u0627\u0645\u0639\u0629 \u0627\u0644\u062f\u0648\u0644 \u0627\u0644\u0639\u0631\u0628\u064a\u0629. (n.d.). Retrieved August11, 2021, from http:\/\/www.leagueofarabstates.net\/en\/Pages\/default.aspx"},{"key":"1734_CR25","unstructured":"Regulations and Coniditions for Good Pharmacovigilance Practices in the State of Libya Version 1 July 2024."},{"key":"1734_CR26","unstructured":"Emirates Drug Establishment (EDE). Guideline on Controls and Conditions for Good Pharmacovigilance Practices for Pharmaceutical Products, July 2026."},{"key":"1734_CR27","unstructured":"Guideline on Good Pharmacovigilance Practices in Oman For MAHs \/ Pharmaceutical Companies. 2017;1\u201330."},{"key":"1734_CR28","unstructured":"Ministry of Health Kingdom of Morocco. Morocco PV Circular 003 Organization of the National Pharmacovigilance System. 2018;519\u201346."},{"issue":"9","key":"1734_CR29","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/pds.4991","volume":"29","author":"TM Alshammari","year":"2020","unstructured":"Alshammari TM, Alenzi KA, Ata SI. National pharmacovigilance programs in Arab countries: a quantitative assessment study. Pharmacoepidemiol Drug Saf. 2020;29(9):1001\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1734_CR30","unstructured":"MHRA GPvP Inspectorate Guide to Marketing Authorization Holder Considerations for Agreements with Pharmacovigilance System Service Providers - MHRA Inspectorate [Internet]. [cited 2020 Aug 2]. Available from: https:\/\/mhrainspectorate.blog.gov.uk\/2018\/01\/22\/mhra-gpvp-inspectorate-guide-to-marketing-authorization-holder-considerations-for-agreements-with-pharmacovigilance-system-service-providers\/."},{"key":"1734_CR31","doi-asserted-by":"crossref","unstructured":"van Leeuwen BP, Prendergast C, Edwards B, Dawson B. Can pharmacovigilance learn from the oil and gas industry, which has been outsourcing for over a century? Therap Innova Regul Sci [Internet]. 2017 Jan 20 [cited 2020 Apr 18];51(1):11\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30235993.","DOI":"10.1177\/2168479016659518"},{"key":"1734_CR32","unstructured":"Kuwait Ministry of Health, Drug and Food Control Sector, Kuwait Pharmacovigilance Center. Kuwait Good Pharmacovigilance Practice Guidelines (KuGVP). Version 6. Kuwait: Ministry of Health; 2026."},{"key":"1734_CR33","unstructured":"Jordan Food and Drug Administration. (2026, March 24). Guideline on Good Pharmacovigilance Practice (GVP) in Jordan (for pharmaceutical products) [Draft guideline for public consultation]. Tawasal. https:\/\/www.tawasal.gov.jo\/Consultations\/Public\/1428\/Guideline_on_Good_Pharmacovigilance_Practice_(GVP)_IN_Jordan_(for_pharmaceutical_products."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01734-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:16:24Z","timestamp":1792041384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01734-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":33,"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01734-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"21 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors all give consent for publication","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are the authors\u2019 personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the employing organizations unless explicitly stated.","order":5,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}